Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma
CAR-T is a potentially lifesaving option for some CLL patients, but Medicare reimbursement may put it out of reach The CLL Society is part of a working group of other blood cancer nonprofits that are trying to find a long term remedy for how to pay for this therapy. Read more.
Related posts